Update shared on04 Aug 2025
Fair value Decreased 5.92%Despite a marked upgrade in consensus revenue growth forecasts and a notable reduction in future P/E, Moderna's analyst price target has been cut from $47.68 to $44.86.
What's in the News
- Moderna has been dropped from the Russell Top 200 Index and its Value variant, but was simultaneously added to the Russell Midcap Index and Russell Midcap Value Index as part of recent index rebalancing (Key Developments, 2025-06-28/30).
- The company faces a potentially changed policy environment, as the U.S. Secretary of Health and Human Services is considering reviewing the use of aluminum adjuvants in vaccines, a move that could affect Moderna and industry peers (Bloomberg, 2025-06-18).
- Progress in HIV vaccine development, an area involving Moderna, is challenged by the reduction of U.S. foreign aid, disrupting ongoing programs and limiting access to critical treatments across Africa (NYT, 2025-06-25).
- Moderna initiated a Phase 1 clinical trial in the U.S. for its novel pan-tumor antigen therapy, mRNA-4106, targeting advanced or metastatic solid tumors; this therapy may enhance treatment options beyond single-antigen approaches (Key Developments, 2025-05-15).
- Moderna further expanded its collaboration with Benchling to digitize and automate its R&D, aiming for a unified, AI-ready platform that streamlines scientific workflows and accelerates discovery (Key Developments, 2025-05-07).
Valuation Changes
Summary of Valuation Changes for Moderna
- The Consensus Analyst Price Target has fallen from $47.68 to $44.86.
- The Consensus Revenue Growth forecasts for Moderna has significantly risen from 2.3% per annum to 5.7% per annum.
- The Future P/E for Moderna has significantly fallen from 55.16x to 48.80x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.